<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444404</url>
  </required_header>
  <id_info>
    <org_study_id>20060347</org_study_id>
    <nct_id>NCT01444404</nct_id>
  </id_info>
  <brief_title>A Study of AMG 820 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      First in human, open-label, sequential dose escalation and expansion study of AMG 820 in
      subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2008</start_date>
  <completion_date type="Actual">February 6, 2014</completion_date>
  <primary_completion_date type="Actual">February 6, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 8, 24 hours post-dose</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose of AMG 820 where clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled is greater than 33%.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tumor associated macrophages (TAMS) as assessed by tumor biopsy at 9 weeks.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 820</intervention_name>
    <description>AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥ 18 years old

          -  Subjects must have a pathologically documented, definitively diagnosed, advanced solid
             tumor

          -  Measurable disease per RECIST 1.1 guidelines

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2

          -  Part 2 - Dose Expansion only: Subjects must have tumor tissue that is accessible for
             core needle biopsy by using minimally invasive procedures and must consent to undergo
             biopsies of the tumor

          -  Able to fast 4 to 6 hours for FDG-PET/CT scan, except subjects with prostate or
             bladder cancers

          -  Competent to sign and date an Institutional Review Board approved informed consent
             form

          -  Adequate hematologic, renal and hepatic function as determined by laboratory blood and
             urine tests

        Exclusion Criteria:

          -  Men and woman of reproductive potential, unwilling to practice a highly effective
             method of birth control for the duration of the study and an additional 4 months after
             receiving the last dose of study drug.

          -  Women who are lactating/breastfeeding or planning to become pregnant during the
             duration of the study

          -  Primary central nervous system (CNS) tumors or CNS metastases

          -  History of presence of hematological malignancies

          -  History of arterial or venous thrombosis within 6 months of study enrollment

          -  History of bleeding diathesis

          -  Myocardial infarction within 6 months of study day 1, symptomatic congestive heart
             failure (New York Heart Association &gt; class II), unstable angina, or unstable cardiac
             arrhythmia requiring medication, or uncontrolled hypertension

          -  Hypertension not adequately controlled with medication (diastolic &gt; 90mmHG; systolic &gt;
             140 mmHG)

          -  Left ventricular ejection fraction (LVEF) ≤ 50%

          -  Active infection requiring (IV) antibiotics within 2 weeks of study enrollment

          -  Known positive test for human immunodeficiency virus (HIV)

          -  Known chronic hepatitis B or hepatitis C infection

          -  Positive test for hepatitis B surface antigen or hepatitis C antibody

          -  Known history of tuberculosis (TB), exposure to active TB-infected individuals, or
             positive TB skin test (tuberculin or purified protein derivative (PPD) test) upon
             study entry (subjects previously vaccinated for TB are not excluded unless there is
             evidence of active TB)

          -  Anti-tumor therapy within 4 weeks of study day 1 including chemotherapy, antibody
             therapy, retinoid therapy, or other investigational agent

          -  Concurrent or prior anticoagulation therapy within 28 days of study day 1

          -  Major surgery within 28 days of study day 1

          -  Any co-morbid medical disorder that may increase the risk of toxicity, in the opinion
             of the investigator or sponsor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27.</citation>
    <PMID>28655795</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

